

NOTICE REGARDING THE LAUNCH OF PHASE II CLINICAL TRIALS CONCERNING DFP-17729

Nippon Chemiphar Co., Ltd.
(TSE: 4539)
April 22, 2021

Delta-Fly Pharma, Inc. and Nippon Chemiphar Co., Ltd. hereby announce that administration of pipeline drug DFP-17729 to the first group of patients participating in the drug's phase II clinical trial began on April 22.

The two companies concluded a licensing agreement for DFP-17729 on March 24, 2020 and started phase I clinical trial for patients suffering from late-stage pancreatic cancer. The safety of this substance was previously confirmed through a successful phase I clinical trial.

DFP-17729 is expected to achieve breakthrough therapeutic effects on cancer by alkalizing microenvironments surrounding cancer cells, which tend to be acidic. As indicated by the published article* released by Delta-Fly Pharma on February 2, 2021, the pipeline drug's antineoplastic effects have already been confirmed through non-clinical trials.

* https://www.jstage.jst.go.jp/article/bpb/44/2/44_b20-00825/_article/-char/en

For further information contact:

Public Relations Department, Nippon Chemiphar Co., Ltd.

E-mail: ir@chemiphar.co.jp